Mini brains predict who benefits from Alzheimer’s treatment
Not every Alzheimer’s patient responds to treatment the same way. That has long been known, but there was no reliable method to predict in advance who would benefit. Miniature brains grown from patients’ own cells may offer a solution.
Organoids are tiny tissue structures grown in the lab from a patient’s stem cells. They mimic a miniature version of an organ and respond to drugs in ways that reflect the patient’s own biology. The researchers used such brain organoids from Alzheimer’s patients and tested how the tissue responded to an antidepressant. The differences between patients were striking.
Not one disease, but many variants
The study shows that Alzheimer’s-related tissue from one patient can respond very differently to a compound than tissue from another patient. This aligns with the broader understanding that Alzheimer’s is not a single uniform disease but rather a cluster of overlapping conditions with similar symptoms. Organoids could eventually help clinicians determine which treatment is most likely to benefit each patient individually, before committing to an expensive or burdensome therapy.
Beyond the organoids themselves, the researchers also analyzed particles released by the mini-brain models, known as extracellular vesicles. These particles carry information about what is happening inside the cells and could potentially serve as a diagnostic tool, the researchers suggest. That remains speculative at this stage.
Personalised care for dementia
This research represents an early step toward personalised dementia care. The technology is not yet ready for clinical use: organoids are costly to produce, consistent cultivation is technically complex, and validation in larger patient groups is still lacking. But the direction is promising. If brain organoids reliably predict how a patient responds to a drug, Alzheimer’s care could become far more targeted in the future.
Want to research this yourself?
Search for example:
- brain organoids personalised medicine
- extracellular vesicles biomarker dementia
- patient-specific Alzheimer model